The Lung Cancer Channel is supported with funding from Johnson & Johnson (Gold) and Takeda (Gold).
VJOncology is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ESMO 2018 | Clinical updates on ALK inhibitor treatment strategies for NSCLC
Frank Griesinger, MD, PhD, of the University of Göttingen, Göttingen, Germany, opens this interview recorded at the European Society for Medical Oncology (ESMO) 2018 Congress, in Munich, Germany, with an optimistic outlook on current treatment strategies for non small cell lung cancer (NSCLC), reporting results from clinical trials testing the efficacy of tyrosine kinase inhibitors (TKIs). Prof. Griesinger also calls for more resistance testing in ALK+ patients and for a greater focus to be placed on correctly sequencing different ALK inhibitors to stratify the right therapy for patients.
